Questions around this news
What clinical evidence for HyBryte was discussed in the journal publication?
The publication in Expert Opinion on Investigational Drugs summarizes clinical trials of synthetic hypericin for cutaneous T-cell lymphoma. Soligenix says the article highlights the therapy’s safety profile, non-mutagenic mechanism and efficacy across studies. The release does not provide specific trial results or numerical measures of efficacy.
What is the status of the FLASH2 Phase 3 trial?
The release says the company is advancing its ongoing FLASH2 Phase 3 trial. It expects an interim analysis in the second quarter of 2026. The announcement does not provide details about enrollment, the interim analysis criteria or when the trial is expected to conclude.
How does photodynamic therapy work?
Photodynamic therapy uses a light-sensitive substance and light to produce an effect in targeted tissue. Depending on the treatment, that effect can damage abnormal cells. The approach generally involves applying or administering the light-sensitive substance, allowing it to reach the target, and then illuminating the area with an appropriate light source.
What does it mean for a treatment mechanism to be non-mutagenic?
A mutagen can cause changes to genetic material. Describing a mechanism as non-mutagenic means it is not understood to cause such changes as part of its action. The term refers to a particular biological property; on its own, it does not establish that a treatment is free of all risks.
Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company focused on rare diseases, announced that a comprehensive summary of clinical trials evaluating HyBryte(TM) (synthetic hypericin) for cutaneous T-cell lymphoma has been published in the peer-reviewed journal Expert Opinion on Investigational Drugs, highlighting the therapy’s safety profile, non-mutagenic mechanism and demonstrated efficacy across studies, while supporting its potential as a first-line treatment option as the company advances its ongoing FLASH2 Phase 3 trial with interim analysis expected in the second quarter of 2026.
To view the full press release, visit https://ibn.fm/hoyUY
About Soligenix Inc.
Soligenix is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. Our Specialized BioTherapeutics business segment is developing and moving toward potential commercialization of HyBryte(TM) (SGX301 or synthetic hypericin sodium) as a novel photodynamic therapy utilizing safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL). With successful completion of the second Phase 3 study, regulatory approvals will be sought to support potential commercialization worldwide. Development programs in this business segment also include expansion of synthetic hypericin (SGX302) into psoriasis, our first-in-class innate defense regulator (IDR) technology, dusquetide (SGX942) for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer, and (SGX945) in Behçet’s Disease.
Our Public Health Solutions business segment includes development programs for RiVax(R), our ricin toxin vaccine candidate, as well as our vaccine programs targeting filoviruses (such as Marburg and Ebola) and CiVax(TM), our vaccine candidate for the prevention of COVID-19 (caused by SARS-CoV-2). The development of our vaccine programs incorporates the use of our proprietary heat stabilization platform technology, known as ThermoVax(R). To date, this business segment has been supported with government grant and contract funding from the National Institute of Allergy and Infectious Diseases (NIAID), the Defense Threat Reduction Agency (DTRA) and the Biomedical Advanced Research and Development Authority (BARDA).
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to SNGX are available in the company’s newsroom at https://ibn.fm/SNGX
Corporate Communications
IBN
Austin, Texas
www.InvestorBrandNetwork.com
512.354.7000 Office
[email protected]
In brief
Soligenix says a peer-reviewed article in Expert Opinion on Investigational Drugs reviews clinical trials of HyBryte, its synthetic hypericin treatment for cutaneous T-cell lymphoma. The company says the publication discusses the therapy’s safety, mechanism and efficacy findings across studies, and supports consideration of HyBryte as a first-line treatment option. Soligenix is also advancing the ongoing FLASH2 Phase 3 trial, with an interim analysis expected in the second quarter of 2026. The company’s development portfolio includes additional programs for rare and other diseases, as well as vaccine candidates. The announcement does not provide detailed trial results or figures from the journal article.
Key takeaways
- A clinical-trial summary on HyBryte appeared in the peer-reviewed journal Expert Opinion on Investigational Drugs.
- Soligenix says the article covers safety, mechanism and efficacy findings for the cutaneous T-cell lymphoma treatment.
- The company is continuing its FLASH2 Phase 3 trial, with interim analysis expected in the second quarter of 2026.
